ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

INDV Indivior Plc

1,506.00
-8.00 (-0.53%)
22 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
Indivior Plc INDV London Ordinary Share
  Price Change Price Change % Share Price Last Trade
-8.00 -0.53% 1,506.00 16:35:12
Open Price Low Price High Price Close Price Previous Close
1,495.00 1,478.00 1,528.00 1,506.00 1,514.00
more quote information »
Industry Sector
PHARMACEUTICALS & BIOTECHNOLOGY

Indivior INDV Dividends History

No dividends issued between 23 Apr 2014 and 23 Apr 2024

Top Dividend Posts

Top Posts
Posted at 22/2/2024 13:19 by casholaa
Fentanyl use is rising, so I take this to mean that the market for indv also increases.
Posted at 20/12/2023 08:27 by adrian j boris
Indivior PLC Indivior Settles Patent Dispute with Actavis (3885X)
20/12/2023 7:00am
UK Regulatory (RNS & others)

Indivior (LSE:INDV)




TIDMINDV

RNS Number : 3885X

Indivior PLC

20 December 2023

Indivior Settles Patent Dispute with Teva Subsidiary Actavis

Richmond, VA and Slough UK, December 20, 2023 - Indivior PLC (LSE/NASDAQ: INDV) , a leading addiction treatment company, today announced that its subsidiaries Indivior Inc. and Indivior UK Limited (together, "Indivior") entered into a settlement agreement with Actavis Laboratories UT, Inc. ("Actavis"), a subsidiary of Teva Pharmaceuticals, to resolve patent disputes regarding Actavis's Abbreviated New Drug Application ("ANDA") for generic buprenorphine and naloxone sublingual film. Under the agreement, Indivior granted Actavis a license to U.S. Patent No. 11,135,216 that would enable Actavis to launch the generic film products identified in its ANDA in the United States no earlier than January 31, 2025, unless the unexpired patent claims are found invalid or unenforceable before that time in a final judicial decision.
Posted at 05/12/2023 16:08 by waldron
Indivior PLC INDV Prevails in Striking Claims in UK Litigation (7595V)
05/12/2023 2:06pm
UK Regulatory (RNS & others)



Tuesday 5 December 2023


TIDMINDV

RNS Number : 7595V


Indivior Prevails in Striking Representative Claims from UK Shareholder Action

Richmond, VA and Slough UK, December 5, 2023 - Indivior PLC (LSE/NASDAQ: INDV) , a leading addiction treatment company, announced that the High Court of Justice of England and Wales has issued a judgment striking out representative claims by Wirral Council as administering authority of Merseyside Pension fund ("Wirral") against Indivior under the Financial Services and Markets Act 2000 ("FSMA"). Wirral's suit was the first attempt by claimants to use representative proceedings for securities claims brought under Sections 90, 90A, and Schedule 10 of the FSMA. The proposed representative proceedings, if allowed, would permit a representative acting on behalf of unnamed claimants to attempt to prove a violation of law without proof of damages, in contrast to ordinary multi-party proceedings, which require proof of liability and damages for each claimant.

In September 2022, Wirral had filed a representative claim generally asserting that Indivior violated the FSMA by making misleading or dishonest statements regarding an alleged fraudulent scheme to switch the market for its SUBOXONE (R) branded products in published information relating to securities. A similar claim was filed against Reckitt Benckiser.

After hearing two days of argument in November 2023, the High Court on December 5 issued a judgment granting Indivior's and Reckitt Benckiser's applications to strike out the representative proceedings. The Court specifically found that it "would be unfair and unjust, and contrary to the overriding objective, to allow the Representative Proceedings to oust the jurisdiction of the Court to case manage the claims from the start." The Court's judgment may be found here .

Wirral and other claimants separately had filed a multi-party action generally alleging the same claims, and levied similar allegations against Reckitt Benckiser Group PLC ("Reckitt Benckiser") in separate actions. Pursuant to the Court's judgment, the claim against Indivior may only proceed in those multi-party proceedings brought by the claimants named in those proceedings.

Wirral may seek permission to appeal the Court's judgment.

About Indivior

Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat addiction and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of substance use disorder (SUD). Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of SUD, including alcohol use disorder and cannabis use disorder. Headquartered in the United States in Richmond, VA, Indivior employs more than 1,000 individuals globally and its portfolio of products is available in 37 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior.

This release is being made by Kathryn Hudson, Company Secretary Indivior PLC.

Media Contacts :

US Media :

Cassie France-Kelly

Vice President, Communications

Indivior PLC

Tel: 804-724-0327

UK Media :

Teneo

Tel: +44 207-353-4200

Investors and Analysts :

Jason Thompson

Vice President, Investor Relations

Indivior PLC

Tel: 804-402-7123

Tim Owens

Director, Investor Relations

Indivior PLC

Tel: 804-263-3978

-ends-





(END) Dow Jones Newswires

December 05, 2023 09:06 ET (14:06 GMT)
Posted at 17/11/2023 16:58 by redwing1
Personally I would rather see cash re-deployed in the business than simply propping up the share price short-term with share buybacks. Maybe more bolt-on acquisitions to further diversify revenues?

I understand and appreciate management's confidence in cashflow and growth prospects, but the cash pile has taken quite a hit in the last two years (with a few payments still yet to be made). I would prefer cash conservation and balance sheet flexibility to buybacks. Even a dividend or two wouldn't go amiss!
Posted at 12/11/2023 12:01 by steeplejack
Its noticeable that second line stocks,especially those that don't pay a dividend,are getting particularly badly hit in these markets.It could be a function of the 'risk free' interest now readily available elsewhere but combined with a general risk aversion,a lot of stocks are vulnerable.Anyway,Indivior isn't alone.
Posted at 09/11/2023 07:38 by ariane
SLOUGH, United Kingdom and RICHMOND, Va., Nov. 9, 2023 /PRNewswire/ -- Indivior PLC (LSE/Nasdaq: INDV) today announced its financial results for the period ending September 30, 2023. The earnings release, investor presentation and webcast are available at www.indivior.com.

Indivior (PRNewsfoto/Indivior)

The earnings release can be found at www.indivior.com/investors

The investor presentation can be found at www.indivior.com/investors (at 7:00 am EST)

There will be a live webcast presentation at 13:00 BST (8:00 am EST) hosted by Mark Crossley, CEO. The details are below.

Webcast link:
Participants may access the presentation telephonically by registering with the following link: [...]
Posted at 21/8/2023 07:12 by adrian j boris
21 August 2023

FOR IMMEDIATE RELEASE

Indivior Reaches Agreement with End Payor Class

to Resolve Their Antitrust Multi-District Litigation Claims

Richmond, VA, August 21, 2023 - Indivior PLC (LSE/Nasdaq: INDV) , a leading addiction treatment company, announced that its subsidiary, Indivior Inc. (the "Company"), has reached an agreement ("Agreement") to resolve the claims brought by the end payor class of litigants ("the End Payor Claimants") in the In re Suboxone Antitrust Litigation multi-district litigation ("MDL"). The Agreement marks the resolution of the End Payor Claimants' claims against the Company in the MDL. The Agreement is subject to initial approval by the United States District Court for the Eastern District of Pennsylvania (the "Court"), a notice period, participation by an appropriate number of end payors and final approval of the Court.

As part of the Agreement, the Company expects to pay $30 million to the End Payor Claimants. The settlement amount is in line with the current provision of $188 million for the MDL. Once the Agreement is approved and entered by the Court, the final settlement amount will be recorded against the $188 million provision. Payment into an escrow account for the benefit of the End Payor Claimants is expected to be made in September of 2023, and funded from the Company's existing cash balance.

"We remain focused on helping those suffering from substance use disorders and mental illness," said Mark Crossley, Chief Executive Officer. "Resolving these legacy legal matters at the right value helps us further our mission for patients and creates greater certainty for our stakeholders."

As set out in the Company's half year report on July 27, 2023, the Company continues to prepare for trial on October 30, 2023, in relation to the remaining claims of the direct purchaser class while at the same time exploring the possibility of settlement at the right value with this class.
Posted at 12/6/2023 07:59 by gibbs1
12 June 2023

For Immediate Release

Indivior to Commence Trading on Nasdaq

Company to Ring Opening Bell June 14 to Bring Awareness to Addiction Treatment;

Company Will Maintain Premium Listing on London Stock Exchange

Richmond, VA, June 12, 2023 - Indivior PLC (LSE: INDV), a global pharmaceutical company working to help change patients' lives by developing medicines to treat substance use disorders (SUD) and serious mental illnesses, today announces that the U.S. Securities & Exchange Commission (SEC) declared its registration statement on Form 20-F effective on June 9. Trading in Indivior ordinary shares on the Nasdaq Global Select Market will commence at U.S. market open today.

Indivior will retain its premium listing on the London Stock Exchange and inclusion in the FTSE 250 index, and its ordinary shares will trade on both exchanges under the ticker symbol "INDV." The Company also notes that no shares are being offered as part of the additional U.S. listing.
Posted at 24/5/2023 09:59 by maywillow
Indivior to Commence Trading on Nasdaq Global Select Market in June
05/24/2023 | 04:17am BST


(MT Newswires) -- Indivior (INDV.L) said Tuesday it expects to start the trading of its ordinary shares on the Nasdaq Global Select Market on June 12 under the ticker INDV.

The pharmaceutical company will retain its premium listing on the London stock exchange and terminate its American depository receipt program, with the shares to be exchanged for Indivior shares on a 1:1 basis.

The US listing remains subject to the approval of the Securities and Exchange Commission.

Shares in Indivior were down more than 2% on Tuesday's close.

Price (GBP): £1470.00, Change: £-31.00, Percent Change: -2.07%
Posted at 07/12/2022 07:52 by grupo guitarlumber
07 December 2022

Indivior Capital Markets Day Highlights Strategy for Shareholder Value Creation

and Attractive Medium-Term Profitable Growth Outlook

- Peak Annual Net Revenue Potential for SUBLOCADE (R) Increased to >$1.5 Billion

- Attractive and Scalable Business Outlined - Expects Strong Net Revenue Growth and Operating Margin Expansion Over the Medium-term

- Disciplined Approach to Capital Allocation Maintained

- NASDAQ Listing Targeted for Spring 2023

This Release Contains Inside Information.

Slough, UK, and Richmond, VA, December 7, 2022 - Indivior PLC (LON: INDV) will hold a Capital Markets Day today in New York City. The event will be hosted by Mark Crossley, Chief Executive Officer, along with members of the Indivior executive leadership team and will detail the Company's strategic growth plans and roadmap for delivering long-term shareholder value.

"We have made tremendous progress executing on our strategic priorities," said Mark Crossley. "We are the pioneer and global leader in addiction treatment and science and are well-positioned to transform the lives of the increasing number of patients affected by the opioid crisis, one of the most urgent public health emergencies of our time. Today, my team and I are excited to provide a deep review of our business and to highlight the compelling opportunities we have to innovate in the treatment of addiction and serious mental illness while delivering profitable growth and significant value creation for shareholders."

-- Increases SUBLOCADE peak annual net revenue (NR) expectations to >$1.5 billion

Indivior expects SUBLOCADE(R) (buprenorphine extended-release) injection to achieve a NR run rate of $1 billion by the end of 2025, driven by its focus on further developing the Organized Health Systems (OHS) channel and pursuing the large opportunity in the U.S. Justice System. Longer term, based on the expected positive market dynamics for buprenorphine medication-assisted treatment (BMAT) and on continued execution against its OHS strategy, Indivior now expects to deliver SUBLOCADE peak potential NR of >$1.5 billion.

-- Expects to achieve attractive double-digit % NR compounded annual growth rate (CAGR) over the medium-term

Indivior expects to achieve a double-digit percentage NR CAGR over the medium-term, driven primarily by SUBLOCADE in the United States and growing NR contribution from PERSERIS(R) (risperidone for extended-release injection). Within this outlook, which is based on its current business portfolio, Indivior also expects a return to NR growth in the Rest of the World driven by new products SUBLOCADE (SUBUTEX (R) PR) and SUBOXONE (R) (buprenorphine/naloxone) Film. Additionally, the Company assumes the U.S. market share of SUBOXONE Film, which it does not promote, will trend towards historical analogs for genericized medicines.

-- Operating margin expansion opportunity from scalable business model

Indivior expects to achieve significant operating margin expansion over the medium-term driven by an improving gross margin and focused management of operating expenses. Following the significant structural growth investments behind SUBLOCADE and PERSERIS in the past two years, selling, general and administrative (SG&A) expenses are expected to grow at a more moderate pace and to decline as a percentage of NR. This impact is expected to be partly offset by an increase in R&D expenses as a percentage of NR towards industry benchmarks as the Company seeks to build a strong and balanced pipeline focused on addiction treatments.

-- Disciplined capital allocation approach focused on driving growth and potential returns of excess cash

In the past two years, Indivior's healthy balance sheet and improved cash flow have supported a balanced approach towards capital allocation, focused on investment in key growth priorities, diversifying the business, delivering shareholder returns and meeting other stakeholder obligations. The recently announced definitive agreement to acquire Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT) is indicative of Indivior's commitment to diversify its product portfolio and to expand its global leadership in addiction treatment and science.

-- Listing on NASDAQ targeted for the Spring of 2023

At its Extraordinary General Meeting (EGM) in September of this year, Indivior received strong support from its shareholders for an additional share listing in the United States. Having carefully evaluated the available options, Indivior has chosen NASDAQ as its U.S. trading venue. The additional listing is expected to elevate Indivior's profile in the Company's largest market and to attract a broader group of biopharma-focused investors and analysts.

The Group reiterates its FY 2022 guidance published on October 27, 2022.

Event Details

Today's event will begin at 8:30am EST and conclude at 12:30pm EST. Due to limited availability, in-person participation is limited to institutional investors and analysts. For those wishing to attend in person, please RSVP to investorrelations@indivior.com and further location details will be provided.

Further details can be found at cmd.indivior.com

To access the live webcast, please click INDV CMD 2022 .

A webcast replay will be available after the event has concluded.

The person responsible for making this announcement is Kathryn Hudson, Company Secretary.

Your Recent History

Delayed Upgrade Clock